Toripalimab Plus FLOT in Locally Advanced Gastric Cancer
Status:
Not yet recruiting
Trial end date:
2025-05-11
Target enrollment:
Participant gender:
Summary
Neoadjuvant therapy for locally advanced gastric cancer is still in the exploratory stage.
With the emergence of immune checkpoint inhibitors, neoadjuvant chemoimmunotherapy is also in
the exploratory stage in locally advanced gastric cancer. At present, chemotherapy combined
with immunotherapy is usually a simple combination of chemotherapeutic drugs and immune
drugs, without taking into account of the influenece of applied sequence. The purpose of this
study is to explore whether the sequence of chemotherapy and immunotherapy influence the
complete pathological response rate in locally advanced gastric cancer.